Navigation Links
Rigel Announces Third Quarter 2011 Financial Results
Date:11/1/2011

SOUTH SAN FRANCISCO, Calif., Nov. 1, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30, 2011.

For the third quarter of 2011, Rigel reported a net loss of $17.9 million, or $0.25 per basic and diluted share, compared to a net income of $50.4 million, or $0.97 and $0.96 per basic and diluted share, respectively, in the same period of 2010. Basic weighted average shares outstanding for the third quarters of 2011 and 2010 were 71.2 million and 52.1 million, respectively. Diluted weighted average shares outstanding for the third quarters of 2011 and 2010 were 71.2 million and 52.8 million, respectively.

Contract revenue for the third quarter of 2011 was $4.4 million, which included a payment of $4.3 million received in the quarter from Merck Serono S.A. and the remaining $0.1 million related to the upfront payment Rigel received for out-licensing its oncology program in June 2011. The collaboration agreement between Rigel and Merck Serono was terminated in 2010 and the program has been returned in full to Rigel. Rigel does not expect to record any further revenue from Merck Serono pursuant to the terminated collaboration agreement. Contract revenue in the third quarter of 2010 was $72.3 million from AstraZeneca AB (AZ), which included amortization of the upfront payment for the exclusive worldwide license agreement for fostamatinib, as well as revenue Rigel earned under that agreement for the initiation of the Phase 3 clinical trial program for fostamatinib and the transfer of the fostamatinib open label extension study to AZ.

Rigel reported total operating expenses of $22.4 million in the third quarter of 2011, compared to $21.9 million in the same period of 2010. The slight increase in operating expenses was primarily due t
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigel to Present at Two Upcoming Investor Conferences
2. Rigel to Present at Wells Fargo Securities Healthcare Conference
3. Rigel to Present at Jefferies Global Healthcare Conference
4. Rigel Announces Pricing of Public Offering of Common Stock
5. Rigel Announces Proposed Public Offering of Common Stock
6. Rigel to Present at Bank of America Merrill Lynch Health Care Conference
7. Rigel Announces First Quarter Financial Results
8. Rigel Announces Fourth Quarter and Year End 2010 Financial Results
9. Rigel to Present at Three Upcoming Investor Conferences
10. Rigel Announces Participation at Two Investor Conferences
11. Rigel to Present at JP Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... SAN MARCOS, Texas , Nov. 21, 2014 /PRNewswire/ ... industrial hemp containing low THC, announces they are now ... is comparable to Charlotte,s Web type strains grown in ... symptoms from other neurological disorders, such as Parkinson,s, MS, ... waiting for US laws to pass, because imported CBD ...
(Date:11/21/2014)... , Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... instruments and consumables for the medical, research, and veterinary ... veterinary and research markets in the United ... stock purchase agreement to acquire 100% of QCR & ... based distribution organization. The transaction closed on November ...
(Date:11/21/2014)... MONTREAL , 21. November 2014 ... hat heute bekannt gegeben, dass ... – EMA) die Kennzeichnung als Orphan-Medizinprodukt ... Produktkandidat des Unternehmens zur Behandlung von ... eine seltene, stark beeinträchtigende genetische Krankheit, ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
... Inc. (NYSE: LDR) announced today that its Board of ... share for the second quarter of fiscal 2012. The dividend will ... on March 9, 2012. About Landauer ... services to determine occupational and environmental radiation exposure and is ...
... BRUSSELS, Feb. 28, 2012 Eli Lilly and Company (NYSE: ... global Innovation Starts Here initiative which supports Lilly,s commitment to ... the world. Two key components of this ... Innovation Fellowship Awards. Through both, Lilly scientists will collaborate with ...
Cached Medicine Technology:Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 2Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 3Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 4Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 5
(Date:11/21/2014)... CDT PLUS! 2015 represents ... includes everything needed to process dental insurance claims. ... , CDT 2015 codes are mandatory for reporting dental ... December 31, 2014. Dental professionals must use HIPAA mandated ... claims. There are significant changes in the CDT coding ...
(Date:11/21/2014)... 21, 2014 TopConsumerReviews.com recently awarded ... industry leader in the relief of depression ... feelings of sadness and depression each year and ... choices. Often, prescription drugs can produce worse side ... are expensive and require regular follow-up visits with ...
(Date:11/21/2014)... FL (PRWEB) November 21, 2014 According ... issued on June 11th, 2014, the inflating system ... rupture when the airbag inflates. The force of inflation ... shrapnel, and the metal shards may pierce the airbag’s ... vehicle’s cabin. , According to a Bloomberg Business ...
(Date:11/21/2014)... London, UK (PRWEB) November 21, 2014 ... only ISO verified healthcare professional panel, today announced two important ... appointment of Roni DasGupta as President of Market Research, Americas ... Market Research, Europe. , Ms. DasGupta joined M3 ... President and most recently Head of Sales. Roni has ...
(Date:11/21/2014)... Dennis Thompson HealthDay ... Injecting beads of gel into the wall of a still-beating ... with severe heart failure, according to a new study. ... oxygen levels and were able to walk hundreds of feet ... Douglas Mann. He is chief of the cardiovascular division at ...
Breaking Medicine News(10 mins):Health News:PMIC Announces CDT PLUS! 2015, the Ultimate Coding Reference for Dentists and Oral Surgeons 2Health News:Depression Relief Product Receives Top 5-Star Rating from TopConsumerReviews.com 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 3Health News:M3 Global Research Announces Leadership Team Promotions in US and EU 2Health News:Gel Implant Might Help Fight Heart Failure 2Health News:Gel Implant Might Help Fight Heart Failure 3
... to open blocked heart arteries a key question has ... expensive drug, abciximab, justified over use of the less-expensive ... be published in the current edition of Value in ... an e-publication, offers clinicians the first large-scale contemporary study ...
... On the Wings to Patient Safety: Innovative Solutions and Tools set ... ... Mich., Sept. 10 The Risk Management and,Patient Safety Institute (RM&PSI) ... conference. The RM&PSI, a,subsidiary of FinCor Holdings Inc. (http://www.fincorholdings.com ), ...
... accuracy and turn-around time for reimbursement, WAYNE, ... in,health information management (HIM) services and technologies, today,announced ... 2X. The key enhancement to PrecyseCode 2X is ... of the medical record,and greater efficiency and speed ...
... Wolf Haldenstein Obtain Third-Largest Settlement,in Securities Fraud Case ... Sept. 10 Judge Morris E.,Lasker of the ... has,granted final approval of a $52.5 million settlement ... Sepracor Inc., a,Massachusetts-based pharmaceutical company (Nasdaq: SEPR ...
... well known healthcare industry executive to start October ... Corporation,(NYSE: STE ) today announced that its ... 53, president and chief executive officer, effective,October 1, ... Company,s Board,effective that date. (Photo: http://www.newscom.com/cgi-bin/prnh/20070910/CLM134 ...
... Institute are the first to discover a mechanism that ... cycle and survival. Their research may result in identification ... , The results of the study appear ... PhD, assistant professor of hematology and oncology at Emory ...
Cached Medicine News:Health News:The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates 2Health News:Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals 2Health News:Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals 3Health News:$52.5 Million Settlement Against Sepracor Inc. Approved 2Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 2Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 3Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 4Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 5Health News:Emory researchers identify signaling protein for multiple myeloma 2Health News:Emory researchers identify signaling protein for multiple myeloma 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: